Drug

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

CI-DRUG-00000218Explore in graph →NCIt C2167 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	0	0	1	1	0	—	—	Jun 1, 2019
Malignant Lung Neoplasm	Phase3	Phase 3	0	0	1	1	0	—	—	Jun 1, 2019

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 21 minutes agoSource updated unknown

Curated evidence

Clinical evidence (14)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–14 of 14 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR VIII1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Clinical trials

Trials with this intervention (1)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–1 of 1 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03727867	Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer	unknown	Phase 3	300	Haihua YangOTHER	1	Jan 30, 2019	clinicaltrials

PTEN Expression1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID774 49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort o… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC	civic

PTEN Expression1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

GlioblastomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID774

49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort o… (full text at CIViC)

PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC

civic

CDKN2A p16 Expression1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Resistance	3	accepted	EID694 In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 pati… (full text at CIViC) PMID 24577117 · Vermorken et al., 2014 · Open in CIViC	civic

CDKN2A p16 Expression1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Head and Neck Squamous Cell Carcinoma

Predictive

Does Not Support Resistance

accepted

EID694

In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 pati… (full text at CIViC)

PMID 24577117 · Vermorken et al., 2014 · Open in CIViC

civic

BCL2L11 Deletion Polymorphism1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID1281 The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensiti… (full text at CIViC) PMID 22426421 · Ng et al., 2012 · Open in CIViC	civic

BCL2L11 Deletion Polymorphism1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Resistance

accepted

EID1281

The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensiti… (full text at CIViC)

PMID 22426421 · Ng et al., 2012 · Open in CIViC

civic

EGFR Amplification1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID948 A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy n… (full text at CIViC) PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC	civic

EGFR Amplification1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID948

A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy n… (full text at CIViC)

PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC

civic

EGFR Overexpression2
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID693 EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone… (full text at CIViC) PMID 22056021 · Pirker et al., 2012 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID737 In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison … (full text at CIViC) PMID 26439803 · Park et al., 2015 · Open in CIViC	civic

EGFR Overexpression2

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID693

EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone… (full text at CIViC)

PMID 22056021 · Pirker et al., 2012 · Open in CIViC

civic

〃

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID737

In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison … (full text at CIViC)

PMID 26439803 · Park et al., 2015 · Open in CIViC

civic

EGFR R832L1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	1	submitted	EID7368 In this systematic pubmed search, EGFR variants associated with Response to EGFR-directed therapy were summarized. One Patient with an EGFR R832L Mutation achieved stable disease with an EGFR Inhibito… (full text at CIViC) PMID 23344264 · Yeh et al., 2013 · Open in CIViC	civic

EGFR R832L1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID7368

In this systematic pubmed search, EGFR variants associated with Response to EGFR-directed therapy were summarized. One Patient with an EGFR R832L Mutation achieved stable disease with an EGFR Inhibito… (full text at CIViC)

PMID 23344264 · Yeh et al., 2013 · Open in CIViC

civic

ERRFI1 Underexpression1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID6379 EGFR activity was markedly decreased during the evolution of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, with a concomitant increase of ERRFI1(Mig6), a negative regulator of EGFR… (full text at CIViC) PMID 23935914 · Chang et al., 2013 · Open in CIViC	civic

ERRFI1 Underexpression1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID6379

EGFR activity was markedly decreased during the evolution of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, with a concomitant increase of ERRFI1(Mig6), a negative regulator of EGFR… (full text at CIViC)

PMID 23935914 · Chang et al., 2013 · Open in CIViC

civic

HRAS G13D1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID699 Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanis… (full text at CIViC) PMID 26561417 · Boidot et al., 2016 · Open in CIViC	civic

HRAS G13D1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Resistance

accepted

EID699

Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanis… (full text at CIViC)

PMID 26561417 · Boidot et al., 2016 · Open in CIViC

civic

KRAS Exon 2 Mutation1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID1208 102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR. dPCR and qPCR results were correlated … (full text at CIViC) PMID 27037411 · Azuara et al., 2016 · Open in CIViC	civic

KRAS Exon 2 Mutation1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Resistance

accepted

EID1208

102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR. dPCR and qPCR results were correlated … (full text at CIViC)

PMID 27037411 · Azuara et al., 2016 · Open in CIViC

civic

KRAS Mutation1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor + Immunomodulatory OligonucleotideCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID943 TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations. PMID 21890455 · Rosa et al., 2011 · Open in CIViC	civic

KRAS Mutation1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor + Immunomodulatory OligonucleotideCombination

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID943

TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.

PMID 21890455 · Rosa et al., 2011 · Open in CIViC

civic

KRAS G12C1
ARS-853 + Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorCombination	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1173 Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. R… (full text at CIViC) PMID 26739882 · Patricelli et al., 2016 · Open in CIViC	civic

KRAS G12C1

ARS-853 + Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorCombination

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID1173

Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. R… (full text at CIViC)

PMID 26739882 · Patricelli et al., 2016 · Open in CIViC

civic

KRAS Activating Mutation1
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Malignant Pancreatic Neoplasm	Predictive	D	Supports Sensitivity Response	1	submitted	EID7184 MAP-ERK kinase (MEK) inhibition in a large PDA cell line panel. Combinations of MEK and EGFR inhibitors induced apoptosis. Combinatorial effect was observed in the epithelial but not mesenchymal subt… (full text at CIViC) PMID 23918833 · Mirzoeva et al., 2013 · Open in CIViC	civic

KRAS Activating Mutation1

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID7184

MAP-ERK kinase (MEK) inhibition in a large PDA cell line panel. Combinations of MEK and EGFR inhibitors induced apoptosis. Combinatorial effect was observed in the epithelial but not mesenchymal subt… (full text at CIViC)

PMID 23918833 · Mirzoeva et al., 2013 · Open in CIViC

civic